FOLFOX4 in the treatment of metastatic colorectal cancer in elderly patients: A prospective study

Archives of Gerontology and Geriatrics

Volumn 52, Issue 1, 2011, Pages 89-93

  Berretta, Massimiliano ^a   Cappellani, Alessandro ^b   Fiorica, Francesco ^c   Nasti, Guglielmo ^d   Frustaci, Sergio ^a   Fisichella, Rossella ^b   Bearz, Alessandra ^a   Talamini, Renato ^a   Lleshi, Arben ^a   Tambaro, Rosa ^e   Cocciolo, Alessandro ^e   Ristagno, Maurizio ^b   Bolognese, Antonio ^f   Basile, Francesco ^b   Meneguzzo, Nereo ^a   Berretta, Salvatore ^b   Tirelli, Umberto ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

^c UNIVERSITY HOSPITAL OF FERRARA   (Italy)

^d NATIONAL CANCER INSTITUTE   (Italy)

^e CATHOLIC UNIVERSITY   (Italy)

^f SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Cancer therapy in elderly; Colorectal cancer; Metastatic cancer; Oxaliplatin

Indexed keywords

FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

AGED; ARTICLE; BLOOD TOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GERIATRIC PATIENT; HUMAN; LIVER METASTASIS; LUNG METASTASIS; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; ORGANOPLATINUM COMPOUNDS; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 78649710820     PISSN: 01674943     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.archger.2010.02.006     Document Type: Article

References (37)

1. Andre T., Louvet C., Raymond E., Tournigand C., De Gramont A. Bimonthly high-dose leucovorin, 5-fluorouracil infusion and oxaliplatin (FOLFOX3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen. Ann. Oncol. 1998, 9:1251-1253.
2. Andre T., Bensmaine M.A., Louvet C., Francois E., Lucas V., Desseigne F., Beerblock K., Bouché O., Carola E., Merrouche Y., Morvan F., Dupont-André G., De Gramont A. Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. J. Clin. Oncol. 1999, 17:3560-3568.
3. Armitage P., Berry G. Statistical Methods in Medical Research 1987, Blackwell Sci. Publication, London.
4. Balducci L., Stanta G. Cancer in the frail patient. A coming epidemic. Hematol. Oncol. Clin. North Am. 2000, 14:235-250.
5. Berardi R., Saladino T., Mari D., Silva R.R., Scartozzi M., Verdecchia L., Onofri A., Cascinu S. Elderly patients with advanced colorectal cancer: tolerability and activity of chemotherapy. Tumori 2005, 91:463-466.
6. Berretta M., Bearz A., Frustaci S., Talamini R., Lombardi D., Fratino L., Lleshi A., Bonanno S., Spartà D., Palmucci S., Berretta S., Tirelli U. Folfox2 in the treatment of advanced colorectal cancer: a comparison between elderly and middle aged patients. J. Chemother. 2008, 20:503-508.
7. Cascinu S., Del Ferro E., Catalano G. Toxicity and therapeutic response to chemotherapy in patients aged 70 years or older with advanced cancer. Am. J. Clin. Oncol. 1996, 19:371-374.
8. Chiara S., Nobile M.T., Vincenti M., Lionetto R., Gozza A., Barzacchi M.C., Sanguineti O., Repetto L., Rosso R. Advanced colorectal cancer in the elderly: results of consecutive trials with 5-fluorouracil-based chemotherapy. Cancer Chemother. Pharmacol. 1998, 42:336-340.
9. Comella P., Natale D., Farris A., Gambardella A., Maiorino L., Massidda B., Casaretti R., Tafuto S., Lorusso V., Leo S., Cannone M. Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma: final results of the Southern Italy Cooperative Oncology Group Trial 0108. Cancer 2005, 104:282-289.
10. De Gramont A., Vignoud J., Tournigand C., Louvet C., Andre T., Varette C., Raymond E., Moreau S., Le Bail N., Krulik M. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur. J. Cancer 1997, 33:214-219.
11. De Gramont A., Figer M., Seymour M., Homerin M., Hmissi A., Cassidy J., Boni C., Cortes-Funes H., Cervantes A., Freyer G., Papamichael D., Le Bail N., Louvet C., Hendler D., De Braud F., Wilson C., Morvan F., Bonetti A. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J. Clin. Oncol. 2000, 18:2938-2947.
12. Edwards B.K., Brown M.L., Wingo P.A., Howe H.L., Ward E., Ries L.A., Schrag D., Jamison P.M., Jemal A., Wu X.C., Friedman C., Harlan L., Warren J., Anderson R.N., Pickle L.W. Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J. Natl. Cancer Inst. 2005, 97:1407-1427.
13. Extermann M., Albrand G., Chen H., Zanetta S., Schonwetter R., Zulian G.B., Cantor A., Droz J.P. Are older French patients as willing as older American patients to undertake chemotherapy?. J. Clin. Oncol. 2003, 21:3214-3219.
14. Feliu J., Escudero P., Llosa F., Bolaños M., Vicent J.M., Yubero A., Sanz-Lacalle J.J., Lopez R., Lopez-Gómez L., Casado E., Gómez-Reina M.J., González-Baron M. Capecitabine as first-line treatment for patients older than 70 years with metastatic colorectal cancer: an Oncopaz Cooperative Group Study. J. Clin. Oncol. 2005, 23:3104-3111.
15. Figer A., Perez-Staub N., Carola E., Tourningard C., Lledo G., Flesh M., Barcelo R., Cervantes A., André T., Colin P., Louvet C., De Gramont A. Folfox in patients aged between 75 and 80 years with metastatic colorectal cancer: an exploratory cohort of the OPTIMOX1 study. Cancer 2007, 110:2666-2671.
16. Goldberg R.M., Tabah-Fisch I., Bleiberg H., De Gramont A., Tournigand C., Andre T., Rothenberg M.L., Green E., Sargent D.J. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J. Clin. Oncol. 2006, 24:4085-4091.
17. Ho C., Ng K., O'Reilly S., Gill S. Outcomes in elderly patients with advanced colorectal cancer treated with capecitabine: a population-based analysis. Clin. Colorectal Cancer 2005, 5:279-282.
18. Hutchins L.F., Unger J.M., Crowley J.J., Coltman, Albain K.S. Underrepresentation of patients 65 years age or older in cancer-treatment trials. N. Engl. J. Med. 1999, 341:2061-2067.
19. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., Thun M.J. Cancer statistics, 2008. CA Cancer J. Clin. 2008, 58:71-96.
20. Kaplan E.L., Meier P. Non-parametric estimation from incomplete observations. J. Am. Stat. Assoc. 1958, 53:457-481.
21. Kim J.H., Oh D.Y., Kim Y.J., Han S.W., Choi I.S., Kim D.W., Im S.A., Kim T.Y., Lee J.S., Heo D.S., Bang Y.J., Kim N.K. Reduced dose intensity Folfox-4 as first line palliative chemotherapy in elderly patients with advanced colorectal cancer. J. Korean Med. Sci. 2005, 20:806-810.
22. Mahoney T., Kuo Y.H., Topilow A., Davis J.M. Stage III colon cancers: why adjuvant chemotherapy is not offered to elderly patients. Arch. Surg. 2000, 135:182-185.
23. Maindrault-Goebel F., Louvet C., Andre T., Carola E., Lotz J.P., Molitor J.L., Garcia M.L., Gilles-Amar V., Izrael V., Krulik M., De Gramont A. Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR. Eur. J. Cancer 1999, 35:1338-1342.
24. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother. Rep. 1966, 50:163-170.
25. NCI (National Cancer Institute), 2001. SEER Cancer Statistics Review, 1975-2001. http://seer.cancer.gov/csr/1975_2001.
26. Popescu R.A., Norman A., Ross P.J., Parikh B., Cunningham D. Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. J. Clin. Oncol. 1999, 17:2412-2418.
27. Raymond E., Chaney S.G., Taamma A., Cvitkovic E. Oxaliplatin: a review of preclinical and clinical studies. Ann. Oncol. 1998, 9:1053-1071.
28. Rosati G., Cordio S. Single-agent irinotecan as second-line weekly chemotherapy in elderly patients with advanced colorectal cancer. Tumori 2006, 92:290-294.
29. Rosati, G., Cordio, S., Bordonaro, R., Caputo, G., Novello, G., Reggiardo, G., Manzione, L., 2009. Capecitabine in combination with oxaliplatin or irinotecan in elderly patients with advanced colorectal cancer: results of a randomized phase II study. Ann. Oncol. (August) (Epub ahead of print).
30. Sargent D.J., Goldberg R.M., Jacobson S.D., Macdonald J.S., Labianca R., Haller D.G., Shepherd L.E., Seitz J.F., Francini G. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N. Engl. J. Med. 2001, 345:1091-1097.
31. Sastre J., Marcuello E., Masutti B., Navarro M., Gil S., Antòn A., Abad A., Aranda E., Maruel J., Valladares M., Maestu I., Carrato A., Vincent J.M., Diaz-Rubio E. Cooperative Group for the Treatment of Digestive Tumors. Irinotecan in combination with fluorouracil in a 48-hour continuos infusion as first line chemotherapy for elderly patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors study. J. Clin. Oncol. 2005, 23:3545-3551.
32. Sastre J., Aranda E., Massuti B., Tabernero J., Chaves M., Abad A., Carrato A., Reina J.J., Queralt B., Gomez-Espana A., Gonzalez-Flores E., Rivera F., Losa F., Garcia T., Sanchez-Rovira P., Maestu I., Diaz-Rubio E. Elderly patients with advanced colorectal cancer derive similar benefit without excessive toxicity after first-line chemotherapy with oxaliplatin-based combinations: comparitive outcomes from the 03-TTD-01 phase III study. Crit. Rev. Oncol. Hematol. 2009, 70:134-144.
33. Schrag D., Cramer L.D., Bach P.B., Begg C.B. Age and adjuvant chemotherapy use after surgery for stage III colon cancer. J. Natl. Cancer Inst. 2001, 93:850-857.
34. Stein B.N., Petrelli N.J., Douglass H.O., Driscoll D.L., Arcangeli G., Meropol N.J. Age and sex are independent predictors of 5-fluorouracil toxicity: analyses of a large scale phase II trial. Cancer 1995, 75:11-17.
35. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., Verweij J., Van Glabbeke M., Van Oosterom A.T., Christian M.C., Gwyther S.G. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 2000, 92:205-216.
36. Vamvakas, L., Athanasiadis, A., Karampeazis, A., Kakolyris, S., Polyzos, A., Kouroussis, C., Ziras, N., Kalbakis, K., Georgoulias, V., Souglakos, J., 2009. Clinical outcome of elderly patients with metastatic colorectal cancer treated with FOLFOXIRI versus FOLFIRI: subgroup analysis of a randomized phase III trial from the Hellenic Oncology Research Group (HORG). Crit. Rev. Oncol. Hematol. (September) (Epub ahead of print).
37. Yancik R. Population aging and cancer: a cross-national concern. Cancer J. 2005, 11:437-441.